Suntrust Banks Trimmed Sony (SNE) Holding, Geode Capital Management Has Upped Ironwood Pharmaceuticals (IRWD) Position

June 19, 2017 - By Dolores Ford

Geode Capital Management Llc increased Ironwood Pharmaceuticals (IRWD) stake by 5.5% reported in 2016Q4 SEC filing. Geode Capital Management Llc acquired 54,326 shares as Ironwood Pharmaceuticals (IRWD)’s stock rose 3.03%. The Geode Capital Management Llc holds 1.04M shares with $15.94 million value, up from 987,867 last quarter. Ironwood Pharmaceuticals now has $2.65 billion valuation. The stock rose 1.08% or $0.19 reaching $17.78 per share. About 134,362 shares traded. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has risen 57.40% since June 19, 2016 and is uptrending. It has outperformed by 40.70% the S&P500.

Suntrust Banks Inc decreased Sony Corp (SNE) stake by 15.45% reported in 2016Q4 SEC filing. Suntrust Banks Inc sold 18,122 shares as Sony Corp (SNE)’s stock rose 13.78%. The Suntrust Banks Inc holds 99,174 shares with $2.78M value, down from 117,296 last quarter. Sony Corp now has $48.69 billion valuation. The stock rose 3.56% or $1.33 reaching $38.66. About 723,530 shares traded. Sony Corp (ADR) (NYSE:SNE) has risen 36.68% since June 19, 2016 and is uptrending. It has outperformed by 19.98% the S&P500.

Since January 11, 2017, it had 0 buys, and 11 insider sales for $3.55 million activity. 30,000 Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares with value of $546,000 were sold by MCCOURT Thomas A. 65,987 shares valued at $1.03M were sold by Hecht Peter M on Wednesday, January 11. Another trade for 3,200 shares valued at $55,008 was sold by OLANOFF LAWRENCE S. 60,000 shares valued at $1.02M were sold by Currie Mark G on Tuesday, March 14. Gilbert Halley E also sold $626,199 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Tuesday, February 14. $31,153 worth of stock was sold by Consylman Gina on Wednesday, February 22. The insider Graney Thomas sold $31,746.

Investors sentiment increased to 1.5 in Q4 2016. Its up 0.10, from 1.4 in 2016Q3. It increased, as 17 investors sold IRWD shares while 37 reduced holdings. 23 funds opened positions while 58 raised stakes. 136.92 million shares or 0.17% more from 136.68 million shares in 2016Q3 were reported. Capstone Investment Advsr Lc has 0.01% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 11,393 shares. Amer Group Inc holds 0% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 74,406 shares. Cap Impact Advsr Ltd Liability has invested 0.13% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Bnp Paribas Prns Sa invested 0.16% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Moreover, Sei Investments has 0.01% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 168,608 shares. Nationwide Fund holds 0.01% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 110,173 shares. Loomis Sayles & Ltd Partnership has invested 0.06% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Prelude Cap Lc reported 23,005 shares. 15,872 were reported by Amalgamated Bankshares. Quantitative Systematic Strategies Limited Liability Co has 0.31% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 49,750 shares. Tfs Capital Ltd Limited Liability Company reported 0.18% stake. California-based Lpl Fincl Limited Liability has invested 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Art Advsrs Limited Liability has 0.08% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Moreover, Century Mngmt Ltd Liability has 0.09% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Us Bankshares De holds 0% or 72 shares.

Among 10 analysts covering Ironwood Pharmaceuticals (NASDAQ:IRWD), 4 have Buy rating, 1 Sell and 5 Hold. Therefore 40% are positive. Ironwood Pharmaceuticals had 20 analyst reports since August 6, 2015 according to SRatingsIntel. As per Friday, February 19, the company rating was maintained by Barclays Capital. Wedbush maintained it with “Neutral” rating and $9 target in Friday, February 19 report. Zacks downgraded the stock to “Hold” rating in Monday, August 10 report. Barclays Capital maintained the stock with “Equal Weight” rating in Wednesday, February 22 report. The firm earned “Neutral” rating on Monday, March 21 by Goldman Sachs. BTIG Research initiated it with “Buy” rating and $15 target in Friday, December 11 report. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) earned “Buy” rating by Mizuho on Monday, October 10. Wedbush maintained Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Thursday, April 28 with “Neutral” rating. The firm earned “Neutral” rating on Monday, October 24 by Wedbush. The firm earned “Buy” rating on Tuesday, May 10 by Mizuho.

Geode Capital Management Llc decreased Gtt Communications Inc (NYSE:GTT) stake by 13,530 shares to 191,664 valued at $5.51M in 2016Q4. It also reduced Cna Finl Corp Com (NYSE:CNA) stake by 13,741 shares and now owns 229,783 shares. Matson Inc (NYSE:MATX) was reduced too.

Suntrust Banks Inc increased Micron Technology Inc (NASDAQ:MU) stake by 44,684 shares to 118,609 valued at $2.60 million in 2016Q4. It also upped Molson Coors Brewing Co (NYSE:TAP) stake by 13,090 shares and now owns 21,203 shares. Royal Dutch Shell Plc was raised too.

Analysts await Sony Corp (ADR) (NYSE:SNE) to report earnings on August, 4. They expect $0.47 EPS, up 193.75% or $0.31 from last year’s $0.16 per share. SNE’s profit will be $591.94M for 20.56 P/E if the $0.47 EPS becomes a reality. After $0.19 actual EPS reported by Sony Corp (ADR) for the previous quarter, Wall Street now forecasts 147.37% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: